FI3761035T3 - Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa - Google Patents
Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa Download PDFInfo
- Publication number
- FI3761035T3 FI3761035T3 FIEP20191942.0T FI20191942T FI3761035T3 FI 3761035 T3 FI3761035 T3 FI 3761035T3 FI 20191942 T FI20191942 T FI 20191942T FI 3761035 T3 FI3761035 T3 FI 3761035T3
- Authority
- FI
- Finland
- Prior art keywords
- protein
- concentration
- sample
- salt
- viscosity
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N2021/258—Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plasma & Fusion (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376788P | 2016-08-18 | 2016-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3761035T3 true FI3761035T3 (fi) | 2024-03-18 |
Family
ID=59746357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20191942.0T FI3761035T3 (fi) | 2016-08-18 | 2017-08-18 | Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11428695B2 (https=) |
| EP (2) | EP3500856B1 (https=) |
| JP (3) | JP6959327B2 (https=) |
| KR (3) | KR102717462B1 (https=) |
| CN (2) | CN115468919A (https=) |
| AU (2) | AU2017313150B2 (https=) |
| BR (1) | BR112019003175A2 (https=) |
| CA (3) | CA3254461A1 (https=) |
| DK (2) | DK3500856T3 (https=) |
| EA (1) | EA201990316A1 (https=) |
| ES (2) | ES2837093T3 (https=) |
| FI (1) | FI3761035T3 (https=) |
| HU (2) | HUE052805T2 (https=) |
| IL (2) | IL264640B2 (https=) |
| MX (2) | MX2019001930A (https=) |
| PL (2) | PL3500856T3 (https=) |
| SG (1) | SG11201900895QA (https=) |
| WO (1) | WO2018035470A1 (https=) |
| ZA (1) | ZA201901035B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3500856T3 (da) | 2016-08-18 | 2020-12-14 | Regeneron Pharma | Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| CN113588582B (zh) * | 2020-04-30 | 2024-05-14 | 上海药明生物技术有限公司 | 蛋白质样品浓度测定方式选择法及测定方法 |
| WO2023095154A1 (en) * | 2021-11-24 | 2023-06-01 | Sensoville Biotech Pvt Ltd | Method for determining changes in a protein's structure |
| WO2023141319A1 (en) * | 2022-01-24 | 2023-07-27 | Amgen Inc. | Methods for detecting antibody self-association |
| CN119832975A (zh) * | 2024-12-24 | 2025-04-15 | 上海药明生物技术有限公司 | 一种蛋白质共处方制剂的稳定性预测方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US771997A (en) | 1903-11-21 | 1904-10-11 | Alfred Palm | Lathe attachment. |
| US4254102A (en) * | 1975-09-08 | 1981-03-03 | Plough, Inc. | Substantive PABA compositions |
| US4080264A (en) | 1976-03-01 | 1978-03-21 | Massachusetts Institute Of Technology | Immunoassay by light scattering spectroscopy |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20050214356A1 (en) * | 2004-03-24 | 2005-09-29 | Joyce Timothy H | Self assembling activation agents targeted using active drug release |
| US20050221507A1 (en) * | 2004-03-30 | 2005-10-06 | Intel Corporation | Method to detect molecular binding by surface-enhanced Raman spectroscopy |
| US7514938B2 (en) | 2004-05-11 | 2009-04-07 | Board Of Regents Of The University And College System Of Nevada, On Behalf Of The University Of Nevada, Reno | Dielectric relaxation spectroscopy apparatus and methods of use |
| TW200621282A (en) | 2004-08-13 | 2006-07-01 | Wyeth Corp | Stabilizing formulations |
| CN101238141B (zh) * | 2005-05-02 | 2016-10-12 | 巴斯福股份公司 | 灵敏检测分析物的新标记策略 |
| WO2007121363A2 (en) | 2006-04-13 | 2007-10-25 | Mississippi State University | An optical apparatus for simultaneously measuring the scattering and concentration signals of macromolecules in a flow cell |
| EP2076287A2 (en) | 2006-10-12 | 2009-07-08 | Wyeth | Methods and compositions with reduced opalescence |
| GB0621050D0 (en) * | 2006-10-23 | 2006-11-29 | Univ Strathclyde | Functionalised polymers for labelling metal surfaces |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| US20110305765A1 (en) * | 2008-11-21 | 2011-12-15 | Board Of Regents, The University Of Texas System | Preparation and methodology of silk fibroin nanoparticles |
| US20140024024A1 (en) * | 2012-07-17 | 2014-01-23 | General Electric Company | Methods of detecting dna, rna and protein in biological samples |
| WO2014192937A1 (ja) * | 2013-05-30 | 2014-12-04 | 公立大学法人大阪府立大学 | 被検出物質の検出装置および方法 |
| IL312865B2 (en) * | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| EP2902503A1 (en) * | 2014-01-31 | 2015-08-05 | Fundación Imdea Nanociencia | Functionalized metal nanoparticles and uses thereof for detecting nucleic acids |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| CN104062287B (zh) | 2014-07-01 | 2017-08-08 | 福建工程学院 | 一种基于纳米金催化的化学发光分析检测铁蛋白的方法 |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| WO2016115475A1 (en) * | 2015-01-18 | 2016-07-21 | Biogen Ma Inc. | Anti-cd40 antibody formulations |
| DK3500856T3 (da) | 2016-08-18 | 2020-12-14 | Regeneron Pharma | Assay til bestemmelse af et proteins potentiale for at selvassociere ved hjælp af koncentrationsafhængig selvinteraktionsnanopartikelspektroskopi |
-
2017
- 2017-08-18 DK DK17761159.7T patent/DK3500856T3/da active
- 2017-08-18 HU HUE17761159A patent/HUE052805T2/hu unknown
- 2017-08-18 BR BR112019003175-8A patent/BR112019003175A2/pt not_active Application Discontinuation
- 2017-08-18 KR KR1020237016537A patent/KR102717462B1/ko active Active
- 2017-08-18 CA CA3254461A patent/CA3254461A1/en active Pending
- 2017-08-18 CN CN202211108451.8A patent/CN115468919A/zh active Pending
- 2017-08-18 CA CA3254460A patent/CA3254460A1/en active Pending
- 2017-08-18 AU AU2017313150A patent/AU2017313150B2/en active Active
- 2017-08-18 HU HUE20191942A patent/HUE066064T2/hu unknown
- 2017-08-18 CN CN201780050825.6A patent/CN109661577B/zh active Active
- 2017-08-18 IL IL264640A patent/IL264640B2/en unknown
- 2017-08-18 DK DK20191942.0T patent/DK3761035T3/da active
- 2017-08-18 SG SG11201900895QA patent/SG11201900895QA/en unknown
- 2017-08-18 JP JP2019508809A patent/JP6959327B2/ja active Active
- 2017-08-18 EP EP17761159.7A patent/EP3500856B1/en active Active
- 2017-08-18 EA EA201990316A patent/EA201990316A1/ru unknown
- 2017-08-18 IL IL307435A patent/IL307435A/en unknown
- 2017-08-18 PL PL17761159T patent/PL3500856T3/pl unknown
- 2017-08-18 US US16/326,238 patent/US11428695B2/en active Active
- 2017-08-18 WO PCT/US2017/047630 patent/WO2018035470A1/en not_active Ceased
- 2017-08-18 PL PL20191942.0T patent/PL3761035T3/pl unknown
- 2017-08-18 FI FIEP20191942.0T patent/FI3761035T3/fi active
- 2017-08-18 ES ES17761159T patent/ES2837093T3/es active Active
- 2017-08-18 EP EP20191942.0A patent/EP3761035B1/en active Active
- 2017-08-18 MX MX2019001930A patent/MX2019001930A/es unknown
- 2017-08-18 KR KR1020227030436A patent/KR102534506B1/ko active Active
- 2017-08-18 KR KR1020197006376A patent/KR102441221B1/ko active Active
- 2017-08-18 CA CA3032361A patent/CA3032361C/en active Active
- 2017-08-18 ES ES20191942T patent/ES2974961T3/es active Active
-
2019
- 2019-02-15 MX MX2023013583A patent/MX2023013583A/es unknown
- 2019-02-18 ZA ZA2019/01035A patent/ZA201901035B/en unknown
-
2021
- 2021-10-07 JP JP2021165510A patent/JP7321227B2/ja active Active
-
2022
- 2022-07-20 US US17/868,983 patent/US11988668B2/en active Active
-
2023
- 2023-07-25 JP JP2023120438A patent/JP2023139189A/ja active Pending
- 2023-12-04 AU AU2023274236A patent/AU2023274236A1/en not_active Abandoned
-
2024
- 2024-04-16 US US18/637,055 patent/US20240280582A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3761035T3 (fi) | Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa | |
| Liu et al. | Combination of micelle collapse and field-amplified sample stacking in capillary electrophoresis for determination of trimethoprim and sulfamethoxazole in animal-originated foodstuffs | |
| JP2019532267A5 (https=) | ||
| Bingaman et al. | Fluorescent dyes modify properties of proteins used in microvascular research | |
| ES2875878T3 (es) | Composición farmacéutica de un anticuerpo anti-VEGF | |
| Comerci et al. | Topologically-guided continuous protein crystallization controls bacterial surface layer self-assembly | |
| JP2023139189A5 (https=) | ||
| JP2019504049A (ja) | ベバシズマブの緩衝された製剤 | |
| EA029215B1 (ru) | Стабильные водные составы адалимумаба | |
| Donatien et al. | Granulocyte-macrophage colony-stimulating factor receptor expression in clinical pain disorder tissues and role in neuronal sensitization | |
| Zhang et al. | Tracking structural transitions of bovine serum albumin in surfactant solutions by fluorescence correlation spectroscopy and fluorescence lifetime analysis | |
| US20150274819A1 (en) | Stable aqueous recombinant protein formulations | |
| Edvinsson et al. | Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors | |
| BR112019021723A2 (pt) | formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab | |
| Fukuda et al. | Small-scale screening method for low-viscosity antibody solutions using small-angle X-ray scattering | |
| KR20170132234A (ko) | 혈관 내피 증식 인자 수용체에 결합하는 핵산 앱타머 | |
| Fazeli et al. | Effect of arginine on pre-nucleus stage of interferon beta-1b aggregation | |
| Courty et al. | Tracking individual proteins in living cells using single quantum dot imaging | |
| Wu et al. | Rapid quantification of protein particles in high-concentration antibody formulations | |
| Malburet et al. | Separation of three strains of polio virus by capillary zone electrophoresis and study of their interaction with aluminum oxyhydroxide | |
| Wanner et al. | Thermo-optical protein characterization for straightforward preformulation development | |
| Zhu et al. | Biomolecular Condensates as Emerging Biomaterials: Functional Mechanisms and Advances in Computational and Experimental Approaches | |
| CA2795596A1 (en) | Agents for treating alzheimer's disease | |
| Yakovleva et al. | Estimation of fluorescence lifetime of lipofuscin fluorophores contained in lipofuscin granules of retinal pigment epithelium of human cadaver eyes without signs of pathology | |
| Hafez et al. | Design of experiment utilization to develop a simple and robust RP-UPLC method for stability indicating method of anti-glaucoma ophthalmic drops |